Tetramethylpyrazine (cas 1124-11-4) ameliorates experimental autoimmune encephalomyelitis by modulating the inflammatory response

Add time:09/29/2019    Source:sciencedirect.com

Multiple sclerosis (MS) is a disabling inflammatory and demyelinating disorder of the central nervous system. Tetramethylpyrazine (cas 1124-11-4) (TMP) has been demonstrated to ameliorate cerebral ischemic injury and spinal cord injury by inhibiting inflammatory cell activation and pro-inflammatory cytokine production. However, the effects of TMP on MS have not been studied. In this study, we evaluated the effects of TMP on the inflammatory response in experimental autoimmune encephalomyelitis (EAE), which is an animal model of MS. TMP (30 mg/kg) treatment significantly reduced the expression levels of NLR Family, Pyrin Domain-Containing 3 Protein inflammasome and caspase-1and decreased inflammatory infiltration and glial activation. Moreover, TMP (30 mg/kg) suppressed the expression of pro-inflammatory cytokines (interleukin-18 [IL-18] and IL-17) and promoted the expression of an anti-inflammatory cytokine (IL-10). The reduced inflammatory response resulted in improvement in clinical scores and decreased demyelination in EAE mice. Therefore, our results demonstrate that TMP (30 mg/kg) improved functional recovery in part by reducing inflammation in EAE mice. TMP may be a potential therapeutic agent for MS therapy.

We also recommend Trading Suppliers and Manufacturers of Tetramethylpyrazine (cas 1124-11-4). Pls Click Website Link as below: cas 1124-11-4 suppliers

Prev:Neuropharmacology and analgesiaProtective effects of Tetramethylpyrazine (cas 1124-11-4) analogue Z-11 on cerebral ischemia reperfusion injury
Next:Full length articleTetramethylpyrazine (cas 1124-11-4) attenuates blood-brain barrier disruption in ischemia/reperfusion injury through the JAK/STAT signaling pathway)